-
公开(公告)号：US11406652B2
公开(公告)日：2022-08-09
申请号：US17256889
申请日：2019-06-28
Applicant: GREEN VALLEY (SHANGHAI) PHARMACEUTICAL CO., LTD. , SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
Inventor： Meiyu Geng , Xianliang Xin , Zhenqing Zhang , Jian Ding
IPC: A61P3/10 , A61K31/715 , A61K31/7032 , A61K31/702 , A61K31/7012 , A61K31/7016
Abstract: The present invention relates to the use of mannuronic diacid oligosaccharide composition in the treatment of diabetes.
-
公开(公告)号：US20210361684A1
公开(公告)日：2021-11-25
申请号：US17256950
申请日：2019-06-28
Applicant: SHANGHAI GREEN VALLEY PHARMACEUTICAL CO., LTD. , SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
Inventor： Meiyu Geng , Xianliang Xin , Zhenqing Zhang , Jian Ding
IPC: A61K31/702 , A61K31/715 , A61K31/7016 , A61K31/7004 , A61P25/04 , A61P25/06
Abstract: The present invention relates to the use of mannuronic diacid oligosaccharide composition in the treatment of pain.
-
公开(公告)号：US20210275570A1
公开(公告)日：2021-09-09
申请号：US17256854
申请日：2019-06-28
Applicant: SHANGHAI GREEN VALLEY PHARMACEUTICAL CO., LTD. , SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
Inventor： Meiyu Geng , Xianliang Xin , Zhenqing Zhang , Jian Ding
IPC: A61K31/734 , A61K31/702 , A61K31/7016 , A61K31/7012 , A61P37/06
Abstract: The present invention relates to the use of mannuronic diacid oligosaccharide composition in the treatment of inflammation.
-
Patent Agency Ranking
公开(公告)号：US20210260085A1
公开(公告)日：2021-08-26
申请号：US17256853
申请日：2019-06-28
Applicant: SHANGHAI GREEN VALLEY PHARMACEUTICAL CO., LTD. , SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
Inventor： Meiyu Geng , Zhenqing Zhang , Yingshen Jin , Zhongping Xiao , Jian Ding
IPC: A61K31/702 , A61P25/28 , A61P29/00
Abstract: The present invention relates to an alginic oligosaccharic diacid composition comprising a mannuronic diacid of Formula (IV) or a pharmaceutically acceptable salt thereof, wherein n is an integer selected from 1 to 9, m is selected from 0, 1 or 2, m′ is selected from 0 or 1, and wherein the total weight of alginic oligosaccharic diacid wherein n=1-5 accounts for more than 60% of the total weight of the composition; the total weight of guluronic acids accounts for less than 50% of the total weight of the composition.
-
公开(公告)号：US10059694B2
公开(公告)日：2018-08-28
申请号：US15529333
申请日：2015-11-18
Applicant: Shanghai Institute of Materia Medica, Chinese Academy of Sciences , GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES
Inventor： Ke Ding , Jian Ding , Shingpan Chan , Meiyu Geng , Xiaomei Ren , Hua Xie , Zhengchao Tu , Yi Chen
IPC: C07D239/48 , C07D401/12 , C07D403/12 , A61K31/505 , A61K31/506 , A61K31/53 , A61K31/5377 , A61K31/4523 , A61P35/00 , A61K31/551
CPC classification number: C07D403/12 , A61K31/4523 , A61K31/505 , A61K31/506 , A61K31/53 , A61K31/5377 , A61K31/551 , C07D239/47 , C07D239/48 , C07D401/02 , C07D401/12
Abstract: Disclosed are a 2-aminopyrimidine compound and pharmaceutical composition and use thereof. The structure of the 2-aminopyrimidine compound is as represented by formula I, in the formula, R1, R2, R3, R4, R5, X, Y, Z, W, (i) being as defined in the specification and the claims. Such compounds effectively inhibit the growth of a variety of tumor cells and have inhibitory effects on EGFR and IGF1R protease, and can be used for preparing antineoplastic drugs and overcome the tolerance induced by the existing drugs such as gefitinib, erlotinib and the like. The compound has selectivity for tumors, in particular the wild-type non-small cell lung cancer and have good pharmacokinetic characteristics.
-
公开(公告)号：US20170283398A1
公开(公告)日：2017-10-05
申请号：US15529333
申请日：2015-11-18
Applicant: Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences , GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES
Inventor： Ke Ding , Jian Ding , Shingpan Chan , Meiyu Geng , Xiaomei Ren , Hua Xie , Zhengchao Tu , Yi Chen
IPC: C07D403/12 , C07D401/12 , C07D239/48
CPC classification number: C07D403/12 , A61K31/4523 , A61K31/505 , A61K31/506 , A61K31/53 , A61K31/5377 , A61K31/551 , C07D239/47 , C07D239/48 , C07D401/02 , C07D401/12
Abstract: Disclosed are a 2-aminopyrimidine compound and pharmaceutical composition and use thereof. The structure of the 2-aminopyrimidine compound is as represented by formula I, in the formula, R1, R2, R3, R4, R5, X, Y, Z, W, (i) being as defined in the specification and the claims. Such compounds effectively inhibit the growth of a variety of tumor cells and have inhibitory effects on EGFR and IGF1R protease, and can be used for preparing antineoplastic drugs and overcome the tolerance induced by the existing drugs such as gefitinib, erlotinib and the like. The compound has selectivity for tumors, in particular the wild-type non-small cell lung cancer and have good pharmacokinetic characteristics.
-
公开(公告)号：US09567342B2
公开(公告)日：2017-02-14
申请号：US14926729
申请日：2015-10-29
Applicant: SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. , SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES
Inventor： Weibo Wang , Meiyu Geng , Jian Ding , Xingdong Zhao , Jing Ai , Qiang Tian , Xia Peng , Weipeng Zhang , Hongbin Liu , Haohan Tan , Ling Chen
IPC: A61K31/506 , C07D487/04 , C07D405/12 , A61K31/519 , A61K31/5377 , A61K45/06 , C07D405/14
CPC classification number: C07D487/04 , A61K31/506 , A61K31/519 , A61K31/5377 , A61K45/06 , C07D405/12 , C07D405/14 , A61K2300/00
Abstract: Disclosed herein are protein kinase inhibitors, more particularly novel pyrimidine derivatives and pharmaceutical compositions thereof, and method of use thereof.
Abstract translation: 本文公开了蛋白激酶抑制剂，更具体地是新颖的嘧啶衍生物及其药物组合物及其使用方法。
-
公开(公告)号：US09206166B2
公开(公告)日：2015-12-08
申请号：US14071953
申请日：2013-11-05
Applicant: SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. , SHANGHAI iNSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES
Inventor： Weibo Wang , Meiyu Geng , Jian Ding , Xingdong Zhao , Jing Ai , Qiang Tian , Xia Peng , Weipeng Zhang , Hongbin Liu , Haohan Tan , Ling Chen
IPC: A61K31/506 , C07D405/12 , A61K31/519 , A61K31/5377 , A61K45/06 , C07D405/14 , C07D487/04
CPC classification number: C07D487/04 , A61K31/506 , A61K31/519 , A61K31/5377 , A61K45/06 , C07D405/12 , C07D405/14 , A61K2300/00
Abstract: Disclosed herein are protein kinase inhibitors, more particularly novel pyrimidine derivatives and pharmaceutical compositions thereof, and method of use thereof.
Abstract translation: 本文公开了蛋白激酶抑制剂，更具体地是新颖的嘧啶衍生物及其药物组合物及其使用方法。
-
-
-
-
-
-
-
Search Results
38
records
(took 0.028 seconds)
